1115 related articles for article (PubMed ID: 33599896)
21. A pharmacovigilance analysis of FDA adverse event reporting system events for romosozumab.
Chen Z; Li M; Li S; Li Y; Wu J; Qiu K; Yu X; Huang L; Chen G
Expert Opin Drug Saf; 2023 Apr; 22(4):339-342. PubMed ID: 36178002
[TBL] [Abstract][Full Text] [Related]
22. Drug-induced interstitial lung disease: a real-world pharmacovigilance study of the FDA Adverse Event Reporting System from 2004 to 2021.
Jiang T; Su H; Xu J; Li C; Zhang N; Li Y; Wu Y; Ni R; Ming Y; Li Z; Li L; Liu Y
Ther Adv Drug Saf; 2024; 15():20420986231224227. PubMed ID: 38293566
[TBL] [Abstract][Full Text] [Related]
23. The cardiovascular safety of antiobesity drugs-analysis of signals in the FDA Adverse Event Report System Database.
Gorelik E; Gorelik B; Masarwa R; Perlman A; Hirsh-Raccah B; Matok I
Int J Obes (Lond); 2020 May; 44(5):1021-1027. PubMed ID: 32152496
[TBL] [Abstract][Full Text] [Related]
24. DPP-4 Inhibitors and Increased Reporting Odds of Bullous Pemphigoid: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS) from 2006 to 2020.
Jedlowski PM; Jedlowski MF; Fazel MT
Am J Clin Dermatol; 2021 Nov; 22(6):891-900. PubMed ID: 34287770
[TBL] [Abstract][Full Text] [Related]
25. Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system.
Zhai Y; Ye X; Hu F; Xu J; Guo X; Zhuang Y; He J
J Immunother Cancer; 2019 Nov; 7(1):286. PubMed ID: 31694698
[TBL] [Abstract][Full Text] [Related]
26. Association of Hyponatraemia and Antidepressant Drugs: A Pharmacovigilance-Pharmacodynamic Assessment Through an Analysis of the US Food and Drug Administration Adverse Event Reporting System (FAERS) Database.
Mazhar F; Pozzi M; Gentili M; Scatigna M; Clementi E; Radice S; Carnovale C
CNS Drugs; 2019 Jun; 33(6):581-592. PubMed ID: 30977109
[TBL] [Abstract][Full Text] [Related]
27. Post-marketing safety of anti-IL-5 monoclonal antibodies (mAbs): an analysis of the FDA Adverse Event Reporting System (FAERS).
Zou SP; Yang HY; Ouyang M; Cheng Q; Shi X; Sun MH
Expert Opin Drug Saf; 2024 Mar; 23(3):353-362. PubMed ID: 37610085
[TBL] [Abstract][Full Text] [Related]
28. Post-marketing safety concerns with nirmatrelvir: A disproportionality analysis of spontaneous reports submitted to the FDA Adverse Event Reporting System.
Zhuang W; Xu J; Wu Y; Yang J; Lin X; Liao Y; Wan J; Weng L; Lin W
Br J Clin Pharmacol; 2023 Sep; 89(9):2830-2842. PubMed ID: 37170890
[TBL] [Abstract][Full Text] [Related]
29. Triptans and serious adverse vascular events: data mining of the FDA Adverse Event Reporting System database.
Roberto G; Piccinni C; D'Alessandro R; Poluzzi E
Cephalalgia; 2014 Jan; 34(1):5-13. PubMed ID: 23921799
[TBL] [Abstract][Full Text] [Related]
30. Adverse events with sodium-glucose co-transporter-2 inhibitors: A global analysis of international spontaneous reporting systems.
Raschi E; Parisotto M; Forcesi E; La Placa M; Marchesini G; De Ponti F; Poluzzi E
Nutr Metab Cardiovasc Dis; 2017 Dec; 27(12):1098-1107. PubMed ID: 29174026
[TBL] [Abstract][Full Text] [Related]
31. Rising cases of drug-induced pulmonary fibrosis: Analysis of the Food and Drug Administration Adverse Event Reporting System (FAERS) database, 2000-2022.
McCall KL; Hennig KR; Abe ZT; Dattler DN; Hurd KL; Portnoy SL; Zagoria ZJ
Pharmacoepidemiol Drug Saf; 2024 May; 33(5):e5797. PubMed ID: 38680101
[TBL] [Abstract][Full Text] [Related]
32. Cardiovascular Events in Men with Prostate Cancer Receiving Hormone Therapy: An Analysis of the FDA Adverse Event Reporting System (FAERS).
Zhang KW; Reimers MA; Calaway AC; Fradley MG; Ponsky L; Garcia JA; Cullen J; Baumann BC; Addison D; Campbell CM; Ghosh AK; Lenihan DJ; Desai NR; Weintraub N; Guha A
J Urol; 2021 Sep; 206(3):613-622. PubMed ID: 33872049
[TBL] [Abstract][Full Text] [Related]
33. Automatic signal extraction, prioritizing and filtering approaches in detecting post-marketing cardiovascular events associated with targeted cancer drugs from the FDA Adverse Event Reporting System (FAERS).
Xu R; Wang Q
J Biomed Inform; 2014 Feb; 47():171-7. PubMed ID: 24177320
[TBL] [Abstract][Full Text] [Related]
34. A real-world pharmacovigilance study of axitinib: data mining of the public version of FDA adverse event reporting system.
Shu Y; Ding Y; Dai B; Zhang Q
Expert Opin Drug Saf; 2022 Apr; 21(4):563-572. PubMed ID: 34918584
[TBL] [Abstract][Full Text] [Related]
35. Drug-Induced Acute Pancreatitis: A Real-World Pharmacovigilance Study Using the FDA Adverse Event Reporting System Database.
Li D; Wang H; Qin C; Du D; Wang Y; Du Q; Liu S
Clin Pharmacol Ther; 2024 Mar; 115(3):535-544. PubMed ID: 38069538
[TBL] [Abstract][Full Text] [Related]
36. A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinib.
Yin Y; Shu Y; Zhu J; Li F; Li J
Sci Rep; 2022 Nov; 12(1):19555. PubMed ID: 36380085
[TBL] [Abstract][Full Text] [Related]
37. Adverse event signal mining and serious adverse event influencing factor analysis of fulvestrant based on FAERS database.
Yin G; Song G; Xue S; Liu F
Sci Rep; 2024 May; 14(1):11367. PubMed ID: 38762547
[TBL] [Abstract][Full Text] [Related]
38. Evaluating the Impact of Black Box Warning Updates on the Reporting of Drug-Related Adverse Events: a Cross Sectional Study of the FAERS Database.
Yavne Y; Amar Shamir R; Shapiro M; Shepshelovich D
Expert Opin Drug Saf; 2023; 22(6):463-468. PubMed ID: 36683587
[TBL] [Abstract][Full Text] [Related]
39. Safety profile of D-penicillamine: a comprehensive pharmacovigilance analysis by FDA adverse event reporting system.
Kumar V; Singh AP; Wheeler N; Galindo CL; Kim JJ
Expert Opin Drug Saf; 2021 Nov; 20(11):1443-1450. PubMed ID: 34259127
[TBL] [Abstract][Full Text] [Related]
40. Adverse event profile differences between rituximab and ocrelizumab: Findings from the FDA Adverse Event Reporting Database.
Caldito NG; Shirani A; Salter A; Stuve O
Mult Scler; 2021 Jun; 27(7):1066-1076. PubMed ID: 32820687
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]